Clinical Trials Logo

Leukemia, Myelogenous, Acute clinical trials

View clinical trials related to Leukemia, Myelogenous, Acute.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01158885 Terminated - Clinical trials for Minimal Residual Disease

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.

NCT ID: NCT01106950 Terminated - Clinical trials for Leukemia, Myelogenous, Acute

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox preparative regimen for the treatment of poor prognosis acute myelogenous leukemia (AML).

NCT ID: NCT01085656 Terminated - Clinical trials for Myelodysplastic Syndromes

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

Start date: February 2011
Phase: Phase 1
Study type: Interventional

This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.